Andrea Cavazzoni

3.2k total citations
76 papers, 2.6k citations indexed

About

Andrea Cavazzoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andrea Cavazzoni has authored 76 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 38 papers in Molecular Biology. Recurrent topics in Andrea Cavazzoni's work include Lung Cancer Treatments and Mutations (29 papers), PI3K/AKT/mTOR signaling in cancer (16 papers) and HER2/EGFR in Cancer Research (16 papers). Andrea Cavazzoni is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), PI3K/AKT/mTOR signaling in cancer (16 papers) and HER2/EGFR in Cancer Research (16 papers). Andrea Cavazzoni collaborates with scholars based in Italy, Netherlands and United Kingdom. Andrea Cavazzoni's co-authors include Roberta Alfieri, Pier Giorgio Petronini, Mara Bonelli, Claudia Fumarola, Silvia La Monica, Daniele Cretella, Maricla Galetti, Marcello Tiseo, Graziana Digiacomo and Andrea Ardizzoni and has published in prestigious journals such as PLoS ONE, The Journal of Physiology and Cancer Research.

In The Last Decade

Andrea Cavazzoni

74 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrea Cavazzoni Italy	35	1.2k	1.1k	996	417	336	76	2.6k
Christine Pirker Austria	31	1.0k 0.9×	1.4k 1.3×	518 0.5×	423 1.0×	448 1.3×	92	3.0k
Claudia Fumarola Italy	33	1.1k 0.9×	1.6k 1.4×	985 1.0×	167 0.4×	536 1.6×	61	2.8k
Elizabeth Buck United States	19	1.1k 0.9×	1.6k 1.5×	594 0.6×	316 0.8×	544 1.6×	54	2.8k
Mara Bonelli Italy	31	952 0.8×	1.3k 1.1×	926 0.9×	124 0.3×	397 1.2×	63	2.5k
Tomislav Dragovich United States	24	1.1k 0.9×	1.0k 0.9×	548 0.6×	177 0.4×	444 1.3×	80	2.3k
Sylvie M. Guichard United Kingdom	33	1.6k 1.3×	2.3k 2.0×	319 0.3×	555 1.3×	445 1.3×	96	4.0k
Giuliana Cassinelli Italy	32	1.0k 0.8×	1.4k 1.2×	425 0.4×	260 0.6×	356 1.1×	64	2.5k
Jeff B. Smaill New Zealand	30	1.0k 0.9×	1.9k 1.6×	542 0.5×	1.0k 2.5×	392 1.2×	95	3.4k
Izabela Podgorski United States	29	859 0.7×	963 0.9×	357 0.4×	310 0.7×	710 2.1×	57	2.5k
Judy R. van Beijnum Netherlands	29	1.2k 1.0×	1.8k 1.6×	497 0.5×	271 0.6×	721 2.1×	53	3.6k

Countries citing papers authored by Andrea Cavazzoni

Since Specialization

Citations

This map shows the geographic impact of Andrea Cavazzoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Cavazzoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Cavazzoni more than expected).

Fields of papers citing papers by Andrea Cavazzoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Cavazzoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Cavazzoni. The network helps show where Andrea Cavazzoni may publish in the future.

Co-authorship network of co-authors of Andrea Cavazzoni

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Cavazzoni. A scholar is included among the top collaborators of Andrea Cavazzoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Cavazzoni. Andrea Cavazzoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alfieri, Roberta, Claudia Fumarola, Mara Bonelli, et al.. (2024). Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines. Biochemical Pharmacology. 228. 116161–116161. 4 indexed citations

Volta, Francesco, Silvia La Monica, Alessandro Leonetti, et al.. (2023). Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators. Targeted Oncology. 18(6). 953–964. 8 indexed citations

Minari, Roberta, Denise Madeddu, Andrea Cavazzoni, et al.. (2022). YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs. JTO Clinical and Research Reports. 3(2). 100278–100278. 6 indexed citations

Digiacomo, Graziana, Francesco Volta, Ingrid Garajová, Rita Balsano, & Andrea Cavazzoni. (2021). Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life. 11(8). 843–843. 17 indexed citations

Cavazzoni, Andrea, Graziana Digiacomo, Roberta Alfieri, et al.. (2020). Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers. 12(3). 666–666. 36 indexed citations

Mazzaschi, Giulia, Roberta Minari, Alessandra Zecca, et al.. (2020). Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. Lung Cancer. 148. 1–11. 82 indexed citations

Monica, Silvia La, Roberta Minari, Daniele Cretella, et al.. (2019). Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. Targeted Oncology. 14(5). 619–626. 38 indexed citations

Monica, Silvia La, Roberta Minari, Daniele Cretella, et al.. (2019). Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of Experimental & Clinical Cancer Research. 38(1). 222–222. 54 indexed citations

Rihawi, Karim, Roberta Alfieri, Michelangelo Fiorentino, et al.. (2018). MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. Translational Oncology. 12(1). 116–121. 35 indexed citations

10.

Rogolino, Dominga, Andrea Cavazzoni, Anna Gatti, et al.. (2017). Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands. European Journal of Medicinal Chemistry. 128. 140–153. 61 indexed citations

11.

Bonelli, Mara, Andrea Cavazzoni, Francesca Saccani, et al.. (2015). Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. Molecular Cancer Therapeutics. 14(8). 1916–1927. 32 indexed citations

12.

Galvani, Elena, Elisa Giovannetti, Francesca Saccani, et al.. (2013). Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer. Neoplasia. 15(1). 61–IN18. 13 indexed citations

13.

Monica, Silvia La, Cristina Caffarra, Francesca Saccani, et al.. (2013). Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification. PLoS ONE. 8(10). e78656–e78656. 46 indexed citations

14.

Cavazzoni, Andrea, Roberta Alfieri, Daniele Cretella, et al.. (2012). Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Molecular Cancer. 11(1). 91–91. 38 indexed citations

15.

Galvani, Elena, Roberta Alfieri, Elisa Giovannetti, et al.. (2012). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design. 19(5). 818–832. 1 indexed citations

16.

Alfieri, Roberta, Maricla Galetti, Roberta Andreoli, et al.. (2011). Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Molecular Cancer. 10(1). 143–143. 37 indexed citations

17.

Mirandola, Prisco, Giuliana Gobbi, Chiara Malinverno, et al.. (2009). TRAIL‐induced apoptosis of FHIT‐negative lung cancer cells is inhibited by FHIT re‐expression. Journal of Cellular Physiology. 220(2). 492–498. 2 indexed citations

18.

Bonelli, Mara, Claudia Fumarola, Roberta Alfieri, et al.. (2008). Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells. Cancer Research. 68. 5441–5441. 1 indexed citations

19.

Alfieri, Roberta, Mara Bonelli, Andrea Cavazzoni, et al.. (2006). Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. The Journal of Physiology. 576(2). 391–401. 57 indexed citations

20.

Cavazzoni, Andrea, Pier Giorgio Petronini, Maricla Galetti, et al.. (2004). Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene. 23(52). 8439–8446. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact